The fund's manager utilizes a passive investment strategy, aiming to closely mirror the returns of its target index. This benchmark is systematically constructed based on specific criteria, focusing on companies engaged in the legal development and application of psychedelic treatments for various medical conditions, adhering to the regulatory frameworks of the respective countries. Generally, the fund will acquire all of the index's constituent securities, maintaining portfolio weightings that approximate their representation within the index.
